“Do It Yourself” Synthetic Cannabinoid Receptor Agonist Precursors as a Ban‐Evading Strategy: Comparison of the Pharmacological Characteristics of Precursors and Their Final Products
- 9 July 2025
- journal article
- Published by Wiley in Drug Testing and Analysis
- Vol. 17 (11) , 2148-2158
Abstract
The enactment of the generic ban on synthetic cannabinoid receptor agonists (SCRAs) in China (2021) added a new flavor to the already diverse and complex SCRA market. Although a large portion of SCRAs is covered by this legislation, a novel strategy to bypass the ban has emerged. So‐called “DIY” (do‐it‐yourself) kits and semi‐finished SCRAs are now being offered online, allowing users or intermediate suppliers to purchase ban‐evading precursors, with the aim that buyers finish the synthesis. Using in vitro β‐arrestin2 recruitment bioassays, we assessed the CB 1 and CB 2 receptor activation potential of three methyl‐3,3‐dimethyl‐butanoate SCRA precursors (MDMB‐ICA, MDMB‐INACA, and MDMB‐5'Me‐INACA), along with some of their potential finished end products, including typical, well‐known but scheduled SCRAs (e.g., 5F‐MDMB‐PINACA and 5F‐MDMB‐PICA), as well as some more recent substances (MDMB‐BUTICA). Whereas tail‐less precursors were weakly active at CB 1 (EC 50 values of 2.34 μM and higher), “finished” SCRAs ((4F‐)MDMB‐BUTI (NA)CA and (5F‐)MDMB‐PI (NA)CA) strongly activated CB 1 (EC 50 1.01–35 nM and E max 366%–488% [relative to JWH‐018]). This emphasizes that this “DIY” synthesis phenomenon poses a serious threat to public health, as it is a new indirect way of “legally” providing users with very potent (known) compounds. Importantly, the “DIY” strategy currently ensures the continued presence of scheduled substances on the market, as exemplified by forensic cases from the United States. While precursors can often not be detected because of a concentration below the limit of detection, it is hypothesized that the presence of SCRAs in at least some of these cases stems from this ban‐evading strategy.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (1S54521N)
This publication has 51 references indexed in Scilit:
- In vitro cannabinoid receptor activity, metabolism, and detection in seized samples of CH‐PIATA, a new indole‐3‐acetamide synthetic cannabinoidDrug Testing and Analysis, 2023
- From JWH‐018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present dayDrug Testing and Analysis, 2022
- A new cannabinoid receptor 1 selective agonist evading the 2021 “China ban”: ADB‐FUBIATADrug Testing and Analysis, 2022
- Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonistsDrug Testing and Analysis, 2022
- A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populationsDrug Testing and Analysis, 2021
- Shape matters: The application of activity‐based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug‐infused papers seized in prisonsDrug Testing and Analysis, 2020
- In vitro activity profiling of Cumyl‐PEGACLONE variants at the CB1 receptor: Fluorination versus isomer explorationDrug Testing and Analysis, 2020
- Chemical profiling of the synthetic cannabinoid MDMB‐CHMICA: Identification, assessment, and stability study of synthesis‐related impurities in seized and synthesized samplesDrug Testing and Analysis, 2019
- Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐tert‐leucineDrug Testing and Analysis, 2019
- Application of an activity‐based receptor bioassay to investigate the in vitro activity of selected indole‐ and indazole‐3‐carboxamide‐based synthetic cannabinoids at CB1 and CB2 receptorsDrug Testing and Analysis, 2018